Skip to main content
 

OVERVIEW OF THE EXPANDED INDICATION

Learn more by watching this video presentation

Click here to access full Prescribing Information.

See pediatric pulmonologist Michael Konstan, MD, present clinical information from Trial 3, which evaluated patients age 6 through 11 who are homozygous for the F508del-CFTR mutation.

Speaker:
Michael W. Konstan, MD
Professor of Pediatrics
Vice Dean for Translational Research
Case Western Reserve University
School of Medicine, Cleveland, Ohio
Dr Konstan will review:
  • Indication and Limitations of Use
  • Important Safety Information
  • Clinical trial data in this patient population
  • Dosage and Administration, dosage adjustments

BREAKTHROUGH TREATMENT FOR THE UNDERLYING CAUSE OF CYSTIC FIBROSIS (CF)

ORKAMBI® (lumacaftor/ivacaftor) targets the complex protein defects of the F508del-CFTR protein1

Lumacaftor and ivacaftor work directly on the CFTR protein to increase chloride ion transport. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.1

More See How ORKAMBI Works

MANAGING THERAPY IN YOUR PATIENTS TAKING ORKAMBI

Discover professional tools to help you initiate conversations with patients taking ORKAMBI

Interactive guides for healthcare providers to help initiate a dialogue on patient beliefs and adherence and patient education.

MEDICATION COVERAGE

home state

Most common plans by state

Select your patient’s state, then download the PDF to view contact information for some of the most common insurers and Medicaid (current as of 08/2016).

  • A member of your team or the patient can contact his/her payer to verify coverage and out-of-pocket expenses
  • Depending on the patient’s insurance plan, benefits may be administered either through the payer or a Pharmacy Benefits Manager (PBM)
vertex GPS logo

Vertex GPS™: Guidance and Patient Support

Access and reimbursement support for your eligible patients.

Contact Vertex GPS

Specialty pharmacies distribute ORKAMBI

Authorized Distributors
Reference:
  1. ORKAMBI [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; September 2016.